Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

Table 3

HIV-1 RNA suppression <50 copies/mL over time, by HIV-1 subtype.

	Darunavir/ritonavir; 800/100 mg once daily	Darunavir/ritonavir; 600/100 mg twice daily
HIV-1 subtype B
Week 4	14/64 (22%)	14/78 (18%)
Week 8	33/64 (52%)	32/78 (41%)
Week 12	44/64 (69%)	43/78 (55%)
Week 24	48/64 (75%)	55/78 (71%)
Week 36	53/64 (83%)	56/78 (72%)
Week 48	53/64 (83%)	56/78 (72%)
HIV-1 subtype non-B
Week 4	14/71 (20%)	13/59 (22%)
Week 8	37/71 (52%)	29/59 (49%)
Week 12	47/71 (66%)	39/59 (66%)
Week 24	58/71 (82%)	51/59 (86%)
Week 36	58/71 (82%)	53/59 (90%)
Week 48	58/71 (82%)	53/59 (90%)

All results shown are (%), unless otherwise stated.